Specifically, proteomic analyses have revealed several CAAT-derived factors, such as leptin and insulin-like growth factor binding protein 2 (IGFBP2), which activate pro-oncogenic pathways, including the PI3K/AKT and STAT3, thereby promoting tumour growth and resistance to therapy [183]. This evidence concerns the gene IGFBP2 and neoplasm.